📊 TNYA Key Takeaways
Is Tenaya Therapeutics, Inc. (TNYA) a Good Investment?
Tenaya is a pre-revenue stage biotech company with significant operating losses of -$93.3M and negative free cash flow of -$68.9M, indicating no commercial validation. While the balance sheet is strong with $100.5M in cash and zero debt, the current burn rate provides only ~1.5 years of runway, making this a high-execution-risk investment dependent on pipeline success.
Why Buy Tenaya Therapeutics, Inc. Stock? TNYA Key Strengths
- Strong balance sheet with $123.3M stockholders equity and zero long-term debt
- Excellent liquidity position with 6.84x current and quick ratios
- Improving diluted EPS trend (+55% YoY) despite continued losses suggests potential operational progress
- Substantial cash reserves of $100.5M provide near-term operational runway
TNYA Stock Risks: Tenaya Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no commercial product validation or revenue generation
- Significant operating cash burn of -$68.3M annually limits strategic flexibility
- High clinical/regulatory execution risk with approximately 1.5 years of cash runway at current burn rates
- Negative returns on equity (-73.5%) and assets (-61.7%) indicate capital is not generating returns
- Potential for substantial shareholder dilution if additional capital raises become necessary
Key Metrics to Watch
- Time to first revenue milestone and clinical trial progression updates
- Quarterly operating cash burn rate trend and cash runway extension
- Clinical pipeline advancement and regulatory approval milestones
Tenaya Therapeutics, Inc. (TNYA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.84x current ratio provides a solid financial cushion.
TNYA Profit Margin, ROE & Profitability Analysis
TNYA vs Healthcare Sector: How Tenaya Therapeutics, Inc. Compares
How Tenaya Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tenaya Therapeutics, Inc. Stock Overvalued? TNYA Valuation Analysis 2026
Based on fundamental analysis, Tenaya Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tenaya Therapeutics, Inc. Balance Sheet: TNYA Debt, Cash & Liquidity
TNYA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tenaya Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.31 indicates the company is currently unprofitable.
TNYA Revenue Growth, EPS Growth & YoY Performance
Tenaya Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TNYA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tenaya Therapeutics, Inc. (CIK: 0001858848)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNYA
What is the AI rating for TNYA?
Tenaya Therapeutics, Inc. (TNYA) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNYA's key strengths?
Claude: Strong balance sheet with $123.3M stockholders equity and zero long-term debt. Excellent liquidity position with 6.84x current and quick ratios.
What are the risks of investing in TNYA?
Claude: Pre-revenue stage with no commercial product validation or revenue generation. Significant operating cash burn of -$68.3M annually limits strategic flexibility.
What is TNYA's revenue and growth?
Tenaya Therapeutics, Inc. reported revenue of N/A.
Does TNYA pay dividends?
Tenaya Therapeutics, Inc. does not currently pay dividends.
Where can I find TNYA SEC filings?
Official SEC filings for Tenaya Therapeutics, Inc. (CIK: 0001858848) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNYA's EPS?
Tenaya Therapeutics, Inc. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TNYA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tenaya Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TNYA stock overvalued or undervalued?
Valuation metrics for TNYA: ROE of -73.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TNYA stock in 2026?
Our dual AI analysis gives Tenaya Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNYA's free cash flow?
Tenaya Therapeutics, Inc.'s operating cash flow is $-68.3M, with capital expenditures of $618.0K.
How does TNYA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -73.5% (avg: 15%), current ratio 6.84 (avg: 2).